Guggenheim Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $65
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
Guggenheim analyst Delma Caiati initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $65.
Guggenheim analyst Delma Caiati initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $65.